Everence Capital Management’s Coherus Oncology CHRS Stock Holding History

Everence Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-28,080	Closed	-$115K	–	747
2023 Q2	$115K	Hold	28,080	–	–	0.01%	712
2023 Q1	$192	Hold	28,080	–	–	0.02%	693
2022 Q4	$222	Hold	28,080	–	–	0.02%	652
2022 Q3	$270K	Hold	28,080	–	–	0.03%	543
2022 Q2	$203K	Buy	28,080 +16,390	+140%	+$143K	0.02%	641
2022 Q1	$151K	Hold	11,690	–	–	0.01%	718
2021 Q4	$187K	Hold	11,690	–	–	0.01%	737
2021 Q3	$188K	Hold	11,690	–	–	0.02%	704
2021 Q2	$162K	Hold	11,690	–	–	0.01%	717
2021 Q1	$171K	Hold	11,690	–	–	0.02%	700
2020 Q4	$203K	Hold	11,690	–	–	0.02%	645
2020 Q3	$214K	Buy	+11,690	New	+$217K	0.02%	564

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Everence Capital Management's CHRS Position: Q3 2023 in Review

Everence Capital Management sold out of Coherus Oncology (CHRS) in Q3 2023, closing a stake of 28,080 shares — an estimated $115K sold.

Everence Capital Management first reported a position in CHRS in Q3 2020 and held it in 12 quarters. The position peaked at $270K in Q3 2022. 169 funds tracked by Wall St. Rank hold CHRS as of Q3 2023.

Everence Capital Management reported no remaining Coherus Oncology position as of Q3 2023 after selling out during the quarter.
Everence Capital Management sold 28,080 Coherus Oncology shares in Q3 2023, an estimated $115K.
Everence Capital Management first reported a position in Coherus Oncology in Q3 2020 and held it in 12 quarters.
Everence Capital Management's Coherus Oncology position peaked at $270K in Q3 2022.
169 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2023.

Based on Everence Capital Management's 13F filing for Q3 2023, filed 16 Oct 2023.